Cytomos, an Edinburgh, Scotland, UK-based biotechnology company, raised £5M in funding.
The round was led by Archangels with participation from Old College Capital, Scottish Enterprise and British Business Bank.
The company intends to use the funds to drive sales of its first commercial product, Celledonia™, built on its cell-analysis technology platform AuraCyt, which is already generating significant market traction.
Led by CEO David Rigterink, Cytomos leverages AuraCyt, a scalable cell analysis platform providing a low-cost, and scalable alternative to current cell analysis systems, to enable biopharma companies to bring novel therapies to market faster and reduce costs.
The business employs 21 people, largely based at its new premises in Roslin, and expects to add another four staff over the next year as it continues to scale operations.
FinSMEs
19/11/2024